文献速递脊柱关节炎

探索难治性中轴型脊柱关节炎:荷兰临床实践登记研究结果

Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于荷兰SpA-Net登记处的横断面研究,分析263例中轴型脊柱关节炎患者,按ASAS定义9.7%为难治性中轴型脊柱关节炎(各变异型3.6-8.7%),1.7%为治疗难治性疾病;当前吸烟(OR=3.1 [95%CI 1.1-8.7])和银屑病史(OR=2.8 [95%CI 1.0-7.6])为相关特征,患者报告结局对分类贡献重要。

要点

  • 约每10例中轴型脊柱关节炎患者中1例符合ASAS难治性定义(9.7%)。
  • 当前吸烟(OR=3.1 [95%CI 1.1-8.7])和银屑病史(OR=2.8 [95%CI 1.0-7.6])与难治性相关。
  • 患者报告结局对难治性中轴型脊柱关节炎的分类有重要贡献。

核心结论

  • 约十分之一的中轴型脊柱关节炎患者为难治性疾病,患者报告结局对难治性中轴型脊柱关节炎分类有重要贡献,当前吸烟和银屑病史为相关特征。

研究设计与样本

  • 横断面研究,使用SpA-Net登记处数据,共分析263例患者;难治性中轴型脊柱关节炎需满足ASAS定义:治疗失败、疾病控制不足(A高疾病活动度ASDAS≥2.1、B活动性疾病征象或C健康相关生活质量降低任一)及患者或风湿科医生视角的管理困难,并探索了仅含A、B或C子标准的三种变异定义;治疗难治性中轴型脊柱关节炎需满足主要ASAS定义、ASDAS≥2.1及CRP≥5 mg/L。

主要发现

  • 9.7%患者为难治性中轴型脊柱关节炎(变异A-C:3.6-8.7%),1.7%为治疗难治性疾病。
  • 治疗失败影响9.9-11.6%患者,疾病控制不足影响79.7%患者(变异A:57.0%,B:44.6%,C:51.4%),管理困难影响51.4-60.2%患者。
  • 当前吸烟(OR=3.1 [95%CI 1.1-8.7])和银屑病史(OR=2.8 [95%CI 1.0-7.6])为相关特征。

关键数值与推荐

  • 难治性中轴型脊柱关节炎的ASAS定义要求治疗失败、疾病控制不足(A:ASDAS≥2.1;B:活动性疾病征象;C:健康相关生活质量降低任一)及管理困难。
  • 治疗难治性中轴型脊柱关节炎要求满足主要ASAS定义、ASDAS≥2.1且CRP≥5 mg/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore (1) the prevalence of difficult-to-manage axial spondyloarthritis (D2M axSpA) in clinical practice according to the Assessment of SpondyloArthritis international Society (ASAS) definition, (2) specific components of this definition contributing most to its fulfilment and (3) associated patient characteristics. METHODS: This cross-sectional study used data from the SpA-Net registry. Fulfilling the ASAS definition required: (1) treatment failure, (2) insufficient disease control (any of: [A] high disease activity (AxSpA Disease Activity Score [ASDAS] ≥2.1), [B] signs of active disease (e.g. peripheral manifestations) or [C] reduced health-related quality of life) and (3) a problematic management situation in the patient's or rheumatologist's perspective. Three variations of the ASAS definition were investigated, including only subcriterion A, B or C in domain 2. Treatment-refractory axSpA required fulfilment of the primary ASAS definition, an ASDAS ≥2.1 and CRP ≥5 mg/L. The prevalence of D2M axSpA per explored definition was calculated, and associated characteristics were assessed using logistic regression analyses. RESULTS: Data from 263 patients were analysed. Overall, 9.7% had D2M axSpA (variations A-C: 3.6-8.7%) and 1.7% had treatment-refractory disease. 'Treatment failure' affected 9.9-11.6% of patients, 'insufficient disease control' affected 79.7% of patients (variation A: 57.0%, B: 44.6%, C: 51.4%) and 'problematic management' affected 51.4-60.2% of patients. Current smoking (OR = 3.1 [95% CI 1.1-8.7]) and a history of psoriasis (OR = 2.8 [95% CI 1.0-7.6]) were associated characteristics. CONCLUSION: One in 10 patients with axSpA have D2M disease. Patient-reported outcomes contribute importantly to the classification of D2M axSpA. Current smoking and a history of psoriasis are associated characteristics.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Smits ML, Webers C, Vonkeman HE, et al. Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry. Rheumatology (Oxford). 2025. PMID: 40036773. doi:10.1093/rheumatology/keaf120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。